Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

China ,United States ,Peking ,Beijing ,Suzhou ,Jiangsu ,Taiwan ,Hong Kong ,Macau ,Chinese ,Yong Huo ,Eli Lilly ,Equecabtagene Autoleucel ,Yujie Zhou ,Innovent Biologics ,Adimab Incyte ,Incyte Corporation ,University First Hospital ,Anzhen Hospital Affiliated To Capital Medical University ,Md Anderson Cancer Center ,Zhongshan Hospital Affiliated To Fudan University ,China National Medical Products Administration ,China Cardiovascular Health ,Clinical Development Of Innovent ,Prnewswire Innovent Biologics Inc ,National Medical Products Administration ,Zhongshan Hospital Affiliated ,Fudan University ,Peking University First Hospital ,Beijing Anzhen Hospital Affiliated ,Capital Medical University ,Lei Qian ,Vice President ,Clinical Development ,Cardiovascular Health ,Disease Report ,Tafolecimab Injection ,Sintilimab Injection ,Bevacizumab Injection ,Adalimumab Injection ,Rituximab Injection ,Pemigatinib Oral Inhibitor ,Ramucirumab Injection ,Selpercatinib Capsules ,Cancer Center ,Mainland China ,Week Randomized ,Placebo Controlled Phase ,Chinese Patients ,Heterozygous Familial Hypercholesterolemia ,Chinese Patients With Hypercholesterolemia ,